XTX Topco’s Verve Therapeutics VERV Stock Holding History

XTX Topco’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-124,964	Closed	–	–	3843
2025 Q3	$0	Buy	124,964 +86,209	+222%	+$955K	﹤0.01%	3325
2025 Q2	$435K	Buy	38,755 +22,960	+145%	+$131K	0.02%	1193
2025 Q1	$72.2K	Buy	+15,795	New	+$106K	﹤0.01%	1930
2024 Q4	–	Sell	-103,348	Closed	-$500K	–	2969
2024 Q3	$500K	Buy	+103,348	New	+$600K	0.04%	818
2024 Q2	–	Sell	-17,011	Closed	-$226K	–	2500
2024 Q1	$226K	Buy	17,011 +6,271	+58%	+$83.2K	0.03%	1077
2023 Q4	$150K	Sell	10,740 -2,429	-18%	-$30.1K	0.03%	1044
2023 Q3	$175K	Buy	13,169 +1,872	+17%	+$30.1K	0.03%	1060
2023 Q2	$212K	Buy	+11,297	New	+$188K	0.04%	966

Other funds holding VERV

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

XTX Topco's VERV Position: Q4 2025 in Review

XTX Topco sold out of Verve Therapeutics (VERV) in Q4 2025, closing a stake of 124,964 shares.

XTX Topco first reported a position in VERV in Q2 2023 and held it in 8 quarters. The position peaked at $500K in Q3 2024. 1 fund tracked by Wall St. Rank holds VERV as of Q4 2025.

XTX Topco reported no remaining Verve Therapeutics position as of Q4 2025 after selling out during the quarter.
XTX Topco sold 124,964 Verve Therapeutics shares in Q4 2025.
XTX Topco first reported a position in Verve Therapeutics in Q2 2023 and held it in 8 quarters.
XTX Topco's Verve Therapeutics position peaked at $500K in Q3 2024.
1 fund tracked by Wall St. Rank held Verve Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.